DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Piperacillin and Tazobactam (Piperacillin Sodium / Tazobactam Sodium) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

PIPERACILLIN AND TAZOBACTAM drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

OVERDOSAGE

There have been postmarketing reports of overdose with piperacillin/tazobactam.  The majority of those events experienced, including nausea, vomiting, and diarrhea, have also been reported with the usual recommended dosages.  Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).

Treatment should be supportive and symptomatic according to the patient’s clinical presentation. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis.  Following a single 3.375 g dose of piperacillin/tazobactam, the percentage of the piperacillin and tazobactam dose removed by hemodialysis was approximately 31% and 39%, respectively (see CLINICAL PHARMACOLOGY ).

CONTRAINDICATIONS

Piperacillin and tazobactam for injection is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or ß-lactamase inhibitors.

REFERENCES

  1. National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Susceptibility Testing; 13th Informational Supplement. NCCLS document M100-S13. NCCLS, Wayne, PA, 2003.
  2. National Committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Test for Bacteria that Grow Aerobically; Approved Standard—5th Edition. NCCLS document M7-A5. NCCLS, Wayne, PA, 2000. 
  3. National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Disk Susceptibility Test; Approved Standard—8th Edition. NCCLS document M2-A8. NCCLS, Wayne, PA, 2003.    
  4. National Committee for Clinical Laboratory Standards, Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—5th ed. NCCLS document M11-A5. NCCLS, Wayne, PA, 2001.      

CLINITEST® and DIASTIX® are registered trademarks of Ames Division, Miles Laboratories, Inc.      

TES-TAPE® is a registered trademark of Eli Lilly and Company.     

Manufactured for:
WG Critical Care, LLC
Paramus, NJ 07652

Made in Italy

Issued:  November 2012
866943/01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017